Bebtelovimab and Remdesivir looked better. A Japanese study demonstrates the efficacy of various monoclonal antibodies and antivirals against Omicron BA.2, BA.4, and BA.5. Let’s review.
URL list from Tuesday, Jul. 26 2022:
Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants | NEJM https://www.nejm.org/doi/full/10.1056…
Microsoft Word – Takashita et al. NEJM_revised_Suppl_20220708.docx https://www.nejm.org/doi/suppl/10.105…
Development of a rapid Focus Reduction Neutralization Test Assay for measuring SARS-CoV-2 neutralizing antibodies – PMC https://www.ncbi.nlm.nih.gov/pmc/arti…
New data published in The New England Journal of Medicine show Evusheld retains neutralising activity against Omicron subvariants, including BA.5 https://www.astrazeneca.com/media-cen…
As Omicron Mutates, Researchers Compare Efficacy of Therapeutic Antibodies and Antivirals | BioSpace https://www.biospace.com/article/omic…
Bebtelovimab | Lilly COVID-19 Treatment https://www.covid19.lilly.com/bebtelo…
Sotrovimab | Emergency Use Authorization (EUA) Information for HCPs https://www.sotrovimab.com/
Casirivimab/imdevimab – Wikipedia https://en.wikipedia.org/wiki/Casiriv…
What is VEKLURY® (remdesivir)? | HCP https://www.vekluryhcp.com/about/
Information for Patients | LAGEVRIO™ (molnupiravir) https://www.lagevrio.com/patients/
PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) For Patients https://www.paxlovid.com